Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00390
|
|||||
| Drug Name |
Fluvoxamine
|
|||||
| Synonyms |
(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; Dumirox; Dumyrox; Faverin; Floxyfral; Fluvoxamina; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum; Fluvoxaminum [INN-Latin]; Luvox (TN); Maveral
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Obsessive compulsive disorder [ICD11:6B20] | Approved | [1] | |||
| Therapeutic Class |
Antidepressants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H21F3N2O2
|
|||||
| Canonical SMILES |
COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
|
|||||
| InChI |
InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
|
|||||
| InChIKey |
CJOFXWAVKWHTFT-XSFVSMFZSA-N
|
|||||
| CAS Number |
CAS 54739-18-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 318.33 | Topological Polar Surface Area | 56.8 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
2.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103112227
,103214033
,103937470
,114182507
,11571264
,117504588
,124749760
,124883444
,124883445
,124883446
,126628425
,126651435
,126666543
,131318468
,134338027
,134339778
,135004455
,137002947
,139157656
,143472592
,144204388
,14899201
,160963524
,162182990
,163392547
,163842794
,164841793
,164841794
,17425133
,26751469
,39297346
,47276707
,47350437
,47425375
,48020069
,48020070
,49699379
,50002999
,50103976
,51005940
,57361188
,7979296
,85788587
,90340960
,92718857
,93166767
,93310594
,96024678
,9774
,99373241
|
|||||
| ChEBI ID |
ChEBI:5138
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Fluvoxamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.